Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is struggling to gain traction with investors, as evidenced by its 0.38 million shares volume. The daily trading volume average remained 0.22 million shares over the course of 3 months. The stock had opened the regular trading at $3.55 and managed a 2.82% price change to reach $3.65 through the close.Adverum Biotechnologies, Inc. (ADVM) Analyst Opinion
Adverum Biotechnologies, Inc. has a consensus outperform rating from 2 Wall Street analysts, and the number of shares currently sold short amount to at least 1.15% of shares outstanding. The stock spiked 21.67% last month and is up 25.86 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover ADVM having a buy-equivalent rating. Analysts have placed a $3.5 price target on Adverum Biotechnologies, Inc., suggesting a -4.11% decline from recent close. It’s currently trading about -13.51% below its 52-week high.
Adverum Biotechnologies, Inc. (ADVM) surprised the stock market in its last reported earnings when it earned -$0.27 a piece versus the consensus-estimated -$0.37. Its revenue totaled $300000 down -34.78% from the previous quarter.Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Intraday View
This stock (ADVM) is ahead of its 52-week low with 52.08%. Its last month’s stock price volatility remained 4.42% which for the week stands at 7.82%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.51% and stays 23.37% away from its 50 days moving average. Over the last five days, shares have faced -3.95% losses and now is up 29.35% since hitting its 200-day moving average of $2.68. Adverum Biotechnologies, Inc. (ADVM) has made its way to a 12-month decline of -12.68%.
Turning to Neos Therapeutics, Inc. (NASDAQ:NEOS), its shares were trading at $8.7 a retreat of $-0.25, on the trading floor. The stock, after opening at $8.95, touched a high of $9 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Neos Therapeutics, Inc. has 1 buy ratings, 1 holds and 0 sells even after the stock tumbled -9.38% from its high of $9.5 to a $244.38 million market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 2 to 2 during a month. Analysts set a 12-month price target of $17.67 a share. The target implies a 103.1% spike from where the shares are currently trading. Also, the current price highlights a discount of 244.83% to analysts’ high consensus price target.Neos Therapeutics, Inc. (NASDAQ:NEOS) Intraday Trading
The counter witnessed a trading volume of 0.32 million shares versus an average volume of 0.63 million shares during last trading session. Its last month’s stock price volatility remained 3.11% which for the week approaches 4.79%. The lowest price the stock reached in the last trading day was $8.7 and compares with the $4.85 52-week low. The stock recovered 79.38% since its low point and has performed 48.72% year-to-date.